Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
作者:Matthew M. Hamilton、Faika Mseeh、Timothy J. McAfoos、Paul G. Leonard、Naphtali J. Reyna、Angela L. Harris、Alan Xu、Michelle Han、Michael J. Soth、Barbara Czako、Jay P. Theroff、Pijus K. Mandal、Jason P. Burke、Brett Virgin-Downey、Alessia Petrocchi、Dana Pfaffinger、Norma E. Rogers、Connor A. Parker、Simon S. Yu、Yongying Jiang、Stephan Krapp、Alfred Lammens、Graham Trevitt、Martin R. Tremblay、Keith Mikule、Keith Wilcoxen、Jason B. Cross、Philip Jones、Joseph R. Marszalek、Richard T. Lewis
DOI:10.1021/acs.jmedchem.1c00679
日期:2021.8.12
Indoleamine 2,3-dioxygenase 1 (IDO1), a heme-containing enzyme that mediates the rate-limiting step in the metabolism of l-tryptophan to kynurenine, has been widely explored as a potential immunotherapeutic target in oncology. We developed a class of inhibitors with a conformationally constrained bicyclo[3.1.0]hexane core. These potently inhibited IDO1 in a cellular context by binding to the apoenzyme
吲哚胺 2,3-双加氧酶 1 (IDO1) 是一种含血红素的酶,可介导l-色氨酸代谢为犬尿氨酸的限速步骤,已被广泛探索为肿瘤学中潜在的免疫治疗靶点。我们开发了一类具有构象受限的双环 [3.1.0] 己烷核心的抑制剂。这些通过与脱辅基酶结合在细胞环境中有效抑制 IDO1,如生化表征和 X 射线晶体学所阐明的那样。SKOV3 肿瘤模型有助于区分化合物,从而鉴定出 IACS-9779 ( 62 ) 和 IACS-70465 ( 71)。IACS-70465 具有出色的细胞效力、强大的药效学反应,并且在人体全血测定中比 linrodostat (BMS-986205) 更有效。IACS-9779 预测人类每日有效剂量低于 1 mg/kg 以维持对 IDO1 的抑制 > 90%,在啮齿动物毒理学和狗心血管研究中显示出可接受的安全范围,以支持推进人类发育的临床前安全性评估。